Mild cognitive impairment: To treat or not to treat

Current Neurology and Neuroscience Reports

Volumn 5, Issue 6, 2005, Pages 455-457

  Kirshner, Howard S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; TACRINE;

AGING; ALZHEIMER DISEASE; AMNESIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; DETERIORATION; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG WITHDRAWAL; HUMAN; MENTAL DEFICIENCY; MINI MENTAL STATE EXAMINATION; PROGNOSIS; RANDOMIZATION; REVIEW; SCORING SYSTEM; TREATMENT FAILURE;

EID: 28244453305     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-005-0033-0     Document Type: Review

References (19)

1. Kral VA: Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962, 86:257-260.
2. Crook T, Bartus RT, Ferris SH, et al.: Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change - report of a National Institute of Mental Health work group. Dev Neuropsychol 1986, 2:261-276.
3. Petersen RC, Smith GE, Waring SC, et al.: Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
4. Petersen RC, Stevens JC, Ganguli M, et al.: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133-1142.
5. Winblad B, Palmer K, Kivipelto M, et al.: Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on mild cognitive impairment. J Intern Med 2004, 256:240-246.
6. Morris JC, Storandt M, Miller JP, et al.: Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001, 58:397-405.
7. Bozoki A, Giordani B, Heidebrink JL, et al.: Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001, 58:411-416.
8. Albert MS, Moss MB, Tanzi R, Jones K: Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc 2001, 7:631-639.
9. Tierney MC, Szalai JP, Snow WG, et al.: A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996, 46:149-154.
10. Okamura N, Arai H, Maruyama M, et al.: Combined analysis of CSF tau levels and iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry 2002, 159:474-476.
11. Jack CR, Petersen RC, Xu YC, et al.: Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397-1403.
12. Small SA, Perera GM, DelaPaz R, et al.: Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 1999, 45:466-472.
13. Dickerson BC, Salat DH, Bates JF, et al.: Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004, 56:27-35.
14. Dubois B, Albert ML: Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol 2004, 3:246-248.
15. Cummings JL: Alzheimer's disease. N Engl J Med 2004, 351:56-67.
16. Salloway S, Ferris S, Kluger A, et al.: Efficacy of donepizil in mild cognitive impairment. A randomized placebo-controlled trial. Neurology 2004, 63:651-657.
17. Petersen RC, Thomas RG, Grundman M, et al.: Vitamin E and donepizil for the treatment of mild cognitive impairment. New Engl J Med 2005, 352:2379-2388.
18. Sano M, Ernesto C, Thomas RG, et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997, 336:1216-1222.
19. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al.: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Int Med 2005, 142:37-46.